Strong India, stumbling specialty: the ₹15,300 Cr quarter that didn't move markets

India domestic business is firing on all cylinders—16% growth, market share up to 8.5% from 8.2%, volume growing 5.4% vs. industry 2%, five new launches in flight. But the rest of the portfolio is stumbling. Specialty medicines (Leqselvi, Unloxcyt) have been on the market for 6–9 months, boast 1,000+ prescribers and positive clinical feedback, yet global specialty revenue remains flat for three consecutive quarters. Emerging markets, which grew 15–20%+ in prior quarters, have fallen off a cliff to 4.2% on geopolitical and macro headwinds. US generics are in structural decline (−9.7%), hurt by Lenalidomide's exit and competitive pressure on base products. Management's response: hold FY27 guidance at high single-digit growth despite delivering 10.5% in Q1, and defend specialty launches as 'early stage'—language that signals caution, not confidence.

Reported PAT of ₹2,901 Cr (+26.5% YoY) looks strong, but there's an earnings quality issue lurking. Adjusted PAT claimed in the transcript is ₹3,089 Cr, while delivered PAT is ₹2,901 Cr—a ₹188 Cr gap (6.5% inflation). Management cited ₹162 Cr in Organon acquisition costs and other adjustments, but the transparency is thin. Isolate the organic number: adjusted PAT ≈ ₹2,713 Cr (ex adjustments), which implies organic YoY growth nearer 15%, not 26.5%. The headline growth leans on one-time items and add-backs the market may not repeat next quarter.

Three downgrades and one upgrade emerged:

Price action: The stock fell 1.36% on day-1 post-result, slid to −2.54% by day-3, and was −2.29% by day-5. The initial fade held—by day-5, the market had priced in the caution of held guidance and specialty stall. The stock now sits at ₹1,930, 5.71% below its all-time high of ₹2,047, yet 21.87% above the 52-week low of ₹1,584. Relative to key moving averages: below the SMA20 (₹1,957), but comfortably above SMA50 (₹1,902) and SMA200 (₹1,787). RSI 32.6 is neutral, signaling neither overbought nor oversold.

Institutional flows: FII ownership has fallen to 14.53% from 15.93% a quarter ago (−140 bps of selling). DII ownership rose to 22.18% from 21.11% (+107 bps of buying). Promoter holding steady at 54.48%. The flow tells a story: foreign investors are trimming exposure (possibly spooked by emerging market slowdown and specialty stall), while domestic institutions are picking up the sellers. Promoter inertia suggests confidence, but FII exit is a yellow flag.

Block activity: One block trade in June: ₹154.4 Cr block, buy-sell between two Government Pension Investment Fund trusts at ₹1,868 (internal rebalancing, no outsider selling). No promoter or insider-linked block activity near the highs—no smoke signal there.